Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499688 | 0.94 | CYP1A2 (0.56) | LMNAGLAHTTSMN1; SMN2TSHR | |
| SCHEMBL6501980 | 0.88 | GAA (0.69) | LMNATSHRHSD17B10APPGAA | |
| SCHEMBL6499395 | 0.86 | BCHE (0.56) | LMNAGLAHTTSMN1; SMN2TSHR | |
| SCHEMBL6507792 | 0.86 | MTNR1A (0.51) | TSHRHSD17B10APPGAA | |
| SCHEMBL6505559 | 0.84 | EPHX2 (0.56) | LMNAGLAHTTSMN1; SMN2TSHR | |
| SCHEMBL6497288 | 0.83 | TSHR (0.53) | TSHRHSD17B10APPGAABCHE | |
| SCHEMBL6498185 | 0.83 | TSHR (0.49) | LMNAGLAHTTSMN1; SMN2TSHR | |
| SCHEMBL6529392 | 0.83 | TSHR (0.48) | LMNAGLAHTTSMN1; SMN2TSHR | |
| SCHEMBL6496215 | 0.82 | GAA (0.50) | LMNAGLAHTTSMN1; SMN2TSHR | |
| SCHEMBL6500610 | 0.81 | GAA (0.59) | LMNATSHRHSD17B10GAABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | LMNA 4603/4885GLA 3902/4885HTT 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.